Ovid Therapeutics Inc (NASDAQ: OVID) on Tuesday, plunged -3.75% from the previous trading day, before settling in for the closing price of $0.30. Within the past 52 weeks, OVID’s price has moved between $0.24 and $3.39.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 284.57%. The company achieved an average annual earnings per share of -66.67%. With a float of $59.51 million, this company’s outstanding shares have now reached $71.11 million.
Let’s determine the extent of company efficiency that accounts for 23 employees. In terms of profitability, gross margin is -2.19%, operating margin of -10404.2%, and the pretax margin is -4557.12%.
Ovid Therapeutics Inc (OVID) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Ovid Therapeutics Inc is 16.32%, while institutional ownership is 54.46%. The most recent insider transaction that took place on Feb 26 ’25, was worth 2,956. In this transaction President and COO of this company sold 5,279 shares at a rate of $0.56, taking the stock ownership to the 73,406 shares. Before that another transaction happened on Feb 26 ’25, when Company’s CBFO sold 3,902 for $0.56, making the entire transaction worth $2,185. This insider now owns 67,973 shares in total.
Ovid Therapeutics Inc (OVID) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -66.67% per share during the next fiscal year.
Ovid Therapeutics Inc (NASDAQ: OVID) Trading Performance Indicators
Ovid Therapeutics Inc (OVID) is currently performing well based on its current performance indicators. A quick ratio of 4.93 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 37.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.35, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.69 in one year’s time.
Technical Analysis of Ovid Therapeutics Inc (OVID)
Looking closely at Ovid Therapeutics Inc (NASDAQ: OVID), its last 5-days average volume was 0.42 million, which is a jump from its year-to-date volume of 0.41 million. As of the previous 9 days, the stock’s Stochastic %D was 38.94%. Additionally, its Average True Range was 0.03.
During the past 100 days, Ovid Therapeutics Inc’s (OVID) raw stochastic average was set at 5.93%, which indicates a significant decrease from 21.64% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 57.20% in the past 14 days, which was lower than the 80.57% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3392, while its 200-day Moving Average is $0.8200. However, in the short run, Ovid Therapeutics Inc’s stock first resistance to watch stands at $0.3009. Second resistance stands at $0.3119. The third major resistance level sits at $0.3209. If the price goes on to break the first support level at $0.2809, it is likely to go to the next support level at $0.2719. Now, if the price goes above the second support level, the third support stands at $0.2609.
Ovid Therapeutics Inc (NASDAQ: OVID) Key Stats
Market capitalization of the company is 20.61 million based on 71,110K outstanding shares. Right now, sales total 570 K and income totals -26,430 K. The company made 130 K in profit during its latest quarter, and -10,240 K in sales during its previous quarter.
